The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Validation of 6-Minute Walk Distance as a Surrogate End Point in Pulmonary Arterial Hypertension Trials
Open accessAbstract
Background—: Nearly all available treatments for pulmonary arterial hypertension have been approved based on change in 6-minute walk distance (Δ6MWD) as a clinically important end point, but its validity as a surrogate end point has never been shown. We aimed to validate the difference in Δ6MWD against the probability of a clinical event in pulmonary arterial hypertension trials. Methods and Results—: First, to determine whether Δ6MWD between baseline and 12 weeks mediated the relationship between treatment assignment and development of clinical events, we conducted a pooled analysis of patient-level data from the 10 randomized placebo-controlled trials previously submitted to the US Food and Drug Administration (n=2404 patients). Second, to identify a threshold effect for the Δ6MWD that indicated a statistically significant reduction in clinical events, we conducted a meta-regression among 21 drug/dose-level combinations. Δ6MWD accounted for 22.1% (95% confidence interval, 12.1%– 31.1%) of the treatment effect ( P <0.001). The meta-analysis showed an average difference in Δ6MWD of 22.4 m (95% confidence interval, 17.4–27.5 m), favoring active treatment over placebo. Active treatment decreased the probability of a clinical event (summary odds ratio, 0.44; 95% confidence interval, 0.33–0.57). The meta-regression revealed a significant threshold effect of 41.8 m. Conclusions—: Our results suggest that Δ6MWD does not explain a large proportion of the treatment effect, has only modest validity as a surrogate end point for clinical events, and may not be a sufficient surrogate end point. Further research is necessary to determine whether the threshold value of 41.8 m is valid for long-term outcomes or whether it differs among trials using background therapy or lacking placebo controls entirely.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An Introduction to the Bootstrap
Efron, B., & Tibshirani, R. J. (1994) · doi:10.1201/9780429246593 · Cited by 40,500
An Introduction to the Bootstrap
Efron, B., & Tibshirani, R. J. (1993) · doi:10.1007/978-1-4899-4541-9 · Cited by 21,230
Echt, D. S., Liebson, P. R., Mitchell, L. B., Peters, R. W., Obias-Manno, D., Barker, A. H., Arensberg, D., Baker, A., Friedman, L., Greene, H. L., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103213241201 · Cited by 3,253
Bosentan Therapy for Pulmonary Arterial Hypertension
Rubin, L. J., Badesch, D. B., Barst, R. J., Galiè, N., Black, C. M., Keogh, A., Pulido, T., Frost, A., Roux, S., Leconte, I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012212 · Cited by 2,726
Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension
Galiè, N., Ghofrani, H. A., Torbicki, A., Barst, R. J., Rubin, L. J., Badesch, D., Fleming, T., Parpia, T., Burgess, G., Branzi, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050010 · Cited by 2,476
Surrogate endpoints in clinical trials: Definition and operational criteria
Prentice, R. L. (1989) · Statistics in Medicine · doi:10.1002/sim.4780080407 · Cited by 2,057
Estimating Mediated Effects in Prevention Studies
Mackinnon, D. P., & Dwyer, J. H. (1993) · Evaluation Review · doi:10.1177/0193841x9301700202 · Cited by 1,937
Inhaled Iloprost for Severe Pulmonary Hypertension
Olschewski, H., Simonneau, G., Galiè, N., Higenbottam, T., Naeije, R., Rubin, L. J., Nikkho, S., Speich, R., Hoeper, M. M., Behr, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020204 · Cited by 1,783
Surrogate End Points in Clinical Trials: Are We Being Misled?
Fleming, T. R., & DeMets, D. L. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-7-199610010-00011 · Cited by 1,651
SIMONNEAU, G., BARST, R. J., GALIE, N., NAEIJE, R., RICH, S., BOURGE, R. C., KEOGH, A., OUDIZ, R., FROST, A., BLACKBURN, S. D., et al. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.6.2106079 · Cited by 1,441
Humbert, M., Sitbon, O., Chaouat, A., Bertocchi, M., Habib, G., Gressin, V., Yaïci, A., Weitzenblum, E., Cordier, J.-F., Chabot, F., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.911818 · Cited by 1,399
Long-term intravenous epoprostenol infusion in primary pulmonary hypertension
Sitbon, O., Humbert, M., Nunes, H., Parent, F., Garcia, G., Hervé, P., Rainisio, M., & Simonneau, G. É. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02012-0 · Cited by 1,383
MIYAMOTO, S., NAGAYA, N., SATOH, T., KYOTANI, S., SAKAMAKI, F., FUJITA, M., NAKANISHI, N., & MIYATAKE, K. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.9906015 · Cited by 1,154
Tadalafil Therapy for Pulmonary Arterial Hypertension
Galiè, N., Brundage, B. H., Ghofrani, H. A., Oudiz, R. J., Simonneau, G., Safdar, Z., Shapiro, S., White, R. J., Chan, M., Beardsworth, A., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.839274 · Cited by 1,103
Galiè, N., Olschewski, H., Oudiz, R. J., Torres, F., Frost, A., Ghofrani, H. A., Badesch, D. B., McGoon, M. D., McLaughlin, V. V., Roecker, E. B., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.742510 · Cited by 1,083
Redelmeier, D. A., Bayoumi, A. M., Goldstein, R. S., & Guyatt, G. H. (1997) · American journal of respiratory and critical care medicine · doi:10.1164/ajrccm.155.4.9105067 · Cited by 1,029
Sitaxsentan Therapy for Pulmonary Arterial Hypertension
Barst, R. J., Langleben, D., Frost, A., Horn, E. M., Oudiz, R., Shapiro, S., McLaughlin, V., Hill, N., Tapson, V. F., Robbins, I. M., et al. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200307-957oc · Cited by 706
A meta-analysis of randomized controlled trials in pulmonary arterial hypertension
Galie, N., Manes, A., Negro, L., Palazzini, M., Bacchi-Reggiani, M. L., & Branzi, A. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehp022 · Cited by 651
Statistical validation of intermediate endpoints for chronic diseases
Freedman, L. S., Graubard, B. I., & Schatzkin, A. (1992) · Statistics in Medicine · doi:10.1002/sim.4780110204 · Cited by 651
The validation of surrogate endpoints in meta-analyses of randomized experiments
Buyse, M., Molenberghs, G., Burzykowski, T., Renard, D., & Geys, H. (2000) · Biostatistics · doi:10.1093/biostatistics/1.1.49 · Cited by 624
Barst, R. J., Langleben, D., Badesch, D., Frost, A., Lawrence, E. C., Shapiro, S., Naeije, R., & Galie, N. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.01.057 · Cited by 478
Bois, R. M. D., Weycker, D., Albera, C., Bradford, W. Z., Costabel, U., Kartashov, A., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201007-1179oc · Cited by 465
Criteria for the Validation of Surrogate Endpoints in Randomized Experiments
Buyse, M., & Molenberghs, G. (1998) · Biometrics · doi:10.2307/2533853 · Cited by 425
The six‐minute walk test: a useful metric for the cardiopulmonary patient
Rasekaba, T., Lee, A. L., Naughton, M. T., Williams, T. J., & Holland, A. E. (2009) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2008.01880.x · Cited by 417
Validity and Reliability of the 6-Minute Walk Test in a Cardiac Rehabilitation Population
Hamilton, D. M., & Haennel, R. G. (2000) · Journal of Cardiopulmonary Rehabilitation · doi:10.1097/00008483-200005000-00003 · Cited by 343
Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension
Provencher, S., Sitbon, O., Humbert, M., Cabrol, S., Jaïs, X., & Simonneau, G. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi728 · Cited by 296
Paciocco, G., Martinez, F. J., Bossone, E., Pielsticker, E., Gillespie, B., & Rubenfire, M. (2001) · European Respiratory Journal · doi:10.1183/09031936.01.17406470 · Cited by 283
Use of Multiple Imputation in the Epidemiologic Literature
Klebanoff, M. A., & Cole, S. R. (2008) · American Journal of Epidemiology · doi:10.1093/aje/kwn071 · Cited by 237
Macchia, A., Marchioli, R., Marfisi, R., Scarano, M., Levantesi, G., Tavazzi, L., & Tognoni, G. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.02.037 · Cited by 232
Surrogate threshold effect: an alternative measure for meta‐analytic surrogate endpoint validation
Burzykowski, T., & Buyse, M. (2006) · Pharmaceutical Statistics · doi:10.1002/pst.207 · Cited by 200
A perfect correlate does not a surrogate make
Baker, S. G., & Kramer, B. S. (2003) · BMC Medical Research Methodology · doi:10.1186/1471-2288-3-16 · Cited by 155
Lassere, M. N. (2007) · Statistical Methods in Medical Research · doi:10.1177/0962280207082719 · Cited by 154
Macchia, A., Marchioli, R., Tognoni, G., Scarano, M., Marfisi, R., Tavazzi, L., & Rich, S. (2010) · American Heart Journal · doi:10.1016/j.ahj.2009.11.028 · Cited by 116
Epidemiology of Pulmonary Arterial Hypertension
Taichman, D. B., & Mandel, J. (2013) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2013.08.010 · Cited by 88
Self-citationGilbert, C. E., Brown, M. C. J., Cappelleri, J. C., Carlsson, M. O., & McKenna, S. P. (2008) · CHEST Journal · doi:10.1378/chest.07-0275 · Cited by 85
SAS Macros for Testing Statistical Mediation in Data With Binary Mediators or Outcomes
Jasti, S., Dudley, W. N., & Goldwater, E. (2008) · Nursing Research · doi:10.1097/01.nnr.0000313479.55002.74 · Cited by 65
Surrogate and Combined End Points in Pulmonary Arterial Hypertension
Ventetuolo, C. E., Benza, R. L., Peacock, A. J., Zamanian, R. T., Badesch, D. B., & Kawut, S. M. (2008) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200803-029sk · Cited by 42
Self-citationEpidemiology of Pulmonary Arterial Hypertension
Taichman, D. B., & Mandel, J. (2007) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2006.11.012 · Cited by 39
Self-citationThe Ethics of Randomized Clinical Trials in Pulmonary Arterial Hypertension
Halpern, S. D., Doyle, R. L., & Kawut, S. M. (2008) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200802-019sk · Cited by 23
Self-citationJohnson, K. R., Freemantle, N., Anthony, D., & Lassere, M. N. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2008.06.004 · Cited by 22
Analyzing the Short-term Effect of Placebo Therapy in Pulmonary Arterial Hypertension
Helman, D. L., Brown, A., Jackson, J. L., & Shorr, A. F. (2007) · CHEST Journal · doi:10.1378/chest.07-0236 · Cited by 17
Huang, J., & Huang, B. (2010) · Statistics in Biopharmaceutical Research · doi:10.1198/sbr.2009.0070 · Cited by 5
Cited by
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv317 · Cited by 6,931
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2015) · European Respiratory Journal · doi:10.1183/13993003.01032-2015 · Cited by 3,172
Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension
Pulido, T., Adzerikho, I., Channick, R. N., Delcroix, M., Galiè, N., Ghofrani, H.-A., Jansa, P., Jing, Z.-C., Le Brun, F.-O., Mehta, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213917 · Cited by 1,443
Riociguat for the treatment of pulmonary arterial hypertension
Ghofrani, H.-A., Galiè, N., Grimminger, F., Grünig, E., Humbert, M., Jing, Z.-C., Keogh, A. M., Langleben, D., Kilama, M. O., Fritsch, A., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209655 · Cited by 1,346
Use of exercise testing in the evaluation of interventional efficacy: an official ERS statement
Puente-Maestu, L., Palange, P., Casaburi, R., Laveneziana, P., Maltais, F., Neder, J. A., O'Donnell, D. E., Onorati, P., Porszasz, J., Rabinovich, R., et al. (2016) · European Respiratory Journal · doi:10.1183/13993003.00745-2015 · Cited by 412
Metadata
- Authors
- Gabler, N. B., French, B., Strom, B. L., Palevsky, H. I., Taichman, D. B., Kawut, S. M., & Halpern, S. D.
- Venue
- Circulation
- Published
- 2012-07-17
- Volume
- 126
- Issue
- 3
- Pages
- 349-356
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2096352797
- Cited by
- 255
- References
- 42
- FWCI
- 23.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.